Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the First Small Molecule Motilin Receptor Agonist Clinical Candida

详细信息    查看全文

• 作者：Susan M. Westaway*^† ; ; Samantha L. Brown^† ; ; Stephen C. M. Fell^† ; ; Christopher N. Johnson^‡ ; ; David T. MacPherson^‡ ; ; Darren
• 刊名：Journal of Medicinal Chemistry
• 出版年：2009
• 出版时间：February 26, 2009
• 年：2009
• 卷：52
• 期：4
• 页码：1180-1189
• 全文大小：193K
• 年卷期：v.52,no.4(February 26, 2009)
• ISSN：1520-4804

文摘

N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.